Figure 5 | Scientific Reports

Figure 5

From: Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

Figure 5

Calculation of the FIH dose from MABEL and NOAEL. The FIH dose from MABEL and NOAEL. The FIH dose from MABEL was calculated as the dose at which the Cmax after 4 h of i.v. infusion of ERY974 is equal to the EC10 value of cytotoxicity assay, combining PK data, and the FIH dose from NOAEL was calculated considering species differences. FIH, first-in-human; MABEL, minimal anticipated biological effect level; NOAEL, observed adverse effect level.

Back to article page